| Business Summary | | Endocardial
Solutions
Inc.
designs,
develops,
and
manufactures
a
minimally
invasive
diagnostic
system
that
diagnoses,
within
the
span
of
a
few
heartbeats,
arrhythmia,
a
potentially
fatal
abnormal
heart
rhythm.
Endocardial
Solutions
believes
that
its
proprietary
EnSite
catheter
and
EnSite
3000
clinical
workstation
(EnSite
System)
is
a
powerful
new
diagnostic
tool
that
will
enable
electrophysiologists
to
rapidly
and
comprehensively
map
arrhythmia
and
improve
the
selection
of
patient
treatment
options. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Endocardial
Solutions
develops,
manufactures
and
markets
the
EnSite
3000
clinical
workstation
and
EnSite
catheter
for
use
by
electrophysiologists
in
diagnosing
and
mapping
abnormal
heart
rhythms
known
as
tachycardias.
For
the
six
months
ended
6/30/01,
revenues
rose
43%
to
$10.2
million.
Net
loss
fell
12%
to
$5
million.
Results
reflect
increased
sales
of
the
Ensite
catheter,
partially
offset
by
increased
research
and
development
and
marketing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| James Bullock, 44 Pres,
CEO | $314K | -- | Richard Omilanowicz, 48 VP,
Manufacturing and Operations | 187K | $41K | Michael Dale, 41 VP
of Sales and Marketing | 228K | -- | Frank Callaghan, 47 VP-
R&D | 186K | -- | Graydon Beatty, 44 CTO | 171K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|